Michael Beauvais > Ropes & Gray LLP > Boston, United States > Lawyer Profile
Ropes & Gray LLP Offices

800 BOYLSTON STREET
BOSTON, MA 02199
MASSACHUSETTS
United States
- Firm Profile
- Go to...
Lawyer Rankings
United States > Healthcare > Life sciences
Ropes & Gray LLP supports key life sciences businesses on transactional, regulatory, litigation, and enforcement matters at every stage of the product development cycle. The firm has a strong corporate and commercial practice, with work across licensing and agreement collaborations, capital markets transactions, and M&A, among others; the latter is evidenced by its representation of ImmunoGen in its $10.1bn sale to AbbVie, completed in February 2024. The team is experienced in IP matters, including Hatch-Waxman litigation and due diligence of patent portfolios, while also supporting emerging companies and working on novel digital health issues. The practice is headed by Washington DC’s Kellie Combs, who specializes in FDA regulatory matters as well as the Public Health Service Act, and commercial transactions and strategic investments expert Michael Beauvais, based in Boston. Other key individuals in the team include DC’s Gregory Levine, who advises clients on FDA regulation of pharmaceuticals, biotech, and medical devices, supporting the company’s regulatory expertise. Marc Rubenstein retired from the practice in early 2025.
Lawyer Rankings
Top Tier Firm Rankings
- Investment fund formation and management > Alternative/hedge funds
- Finance > Commercial lending
- Dispute resolution > E-discovery
- Industry focus > Education
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Securities litigation: defense
- Intellectual property > Patents: licensing
- Healthcare > Life sciences
- Investment fund formation and management > Mutual/registered/exchange-traded funds
- Tax > Not-for-profit (Fortune 1000 private foundations, national trade associations, and charities)
- Intellectual property > Patents: licensing
- Healthcare > Service providers
Firm Rankings
- Finance > Capital markets: equity offerings
- Tax > Not-for-profit (Fortune 1000 private foundations, national trade associations, and charities)
- Intellectual property > Patents: licensing
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Investment fund formation and management > Private equity funds (including venture capital)
- Tax > US taxes: non-contentious
- M&A/corporate and commercial > Shareholder activism
- Finance > Capital markets: high-yield debt offerings
- Antitrust > Cartel
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Real estate > Real estate
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Securities litigation: defense
- Government > State attorneys general
- Finance > Structured finance: derivatives and structured products
- Finance > Structured finance: securitization
- Labor and employment > Workplace and employment counseling
- Finance > Capital markets: high-yield debt offerings
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Fintech
- Antitrust > Merger control
- International trade and national security > National Security
- Intellectual property > Patents: litigation (full coverage)
- Intellectual property > Patents: litigation (International Trade Commission)
- Media, technology and telecoms > Technology transactions
- Antitrust > Civil litigation/class actions: defense
- Finance > Commercial lending > Advice to direct lenders/private credit
- Finance > Commercial lending: Advice to bank lenders
- M&A/corporate and commercial > Venture capital and emerging companies
- Finance > Capital markets: debt offerings
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Finance > Financial services regulation
- International trade and national security > Customs, export controls and economic sanctions